In the absence of TOP2A-specific anthracyclines, TOP2B-selective catalytic inhibitors pose a unique opportunity to strategically prevent TOP2B poisoning in the heart while leaving TOP2A in tumours susceptible to anthracycline poisoning. This evidence concerns the gene TOP2A and neoplasm.